Naveen Mummudi

It's Breast Cancer Around the Globe! 🥳 Sim reprises his award-winning concept with breast cancer experts @Sushilberiwal, @AnnaKirby17, and @drrevathyk! The group examines screening and how a wide range of cases might be managed in the US, UK, and India. #MedEd #RadOnc

🔥🚨@OncoAlert Hot Off the Press BIG NEWS Press Release by @AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️#OS & ⬆️#PFS 👇🏼 astrazeneca.com/media-centre/p…

The standard of care for stage III NSCLC changes once again; Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc astrazeneca.com/media-centre/p…

With a #HSPR Project Grant, Drs @beverleyessue @drrevathyk @daniellerodin @mandira_sa51302 & partners are addressing breast cancer's economic burden in India to promote equity in access to care. Read more tinyurl.com/yj4848bt #BreastCancerAwarenessMonth

New research - Liu et al - Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial thelancet.com/journals/langa… #GITwitter #OncTwitter @OncoAlert

A compilation of my threads about academic medicine, research, oncology, radiation oncology, prostate cancer, metastasis, public health, and more: bit.ly/ZaorskyEducati…

Radiotherapy sentiment in @NYTimes is eye-opening. Since 2009, over half of articles show negative bias towards RT, while only 1/4 are positive. Despite major advancements in tech like MR-Linac, adaptive RT, & heavy ions, media celebration is scarce. thegreenjournal.com/article/S0167-… 1/7

An amazing read - 'Simone's maxims'!

AROI Inauguration 🪔🪔 @icc_2023 by office bearers of AROI & MHAROI with @ASTRO_org president @DrHowardSandler as chief guest 📸 L-R @KaustavT @snsenapati Dr Rajesh Vasishtha Dr DN Sharma Dr JP Agarwal @DrHowardSandler Dr Manoj Gupta @sarbani30 Dr Madhup Rastogi @vsrinivasan

🔥Neoadjuvant RCTX + surgery vs active surveillance for oesophageal cancer SANO trial put into context by Magnus Nilsson @ #ESMO2023 🧐in depth discussion, food for thoughts... @myESMO

#ESMO23 Dr. Ze-Rui Zhao presents the SACTION-1 study of neoadjuvant SBRT + chemo-immunotherapy for resectable NSCLC. SBRT was 8Gy + 3d and tislelizumab + chemotherapy started within a week for 2 cycles before surgical resection.

So excited to present🎯DART RCT at the #ASTRO2023 late-breaking abstract and press sessions 👉Diagnostic CT-based planning⬇️pt time at cancer center from almost 5hrs to <0.5hrs w/out detriment to plan quality 👉Pts reported⬇️time burden Do you🎯? Join our Delphi study!

Congratulations @supriyasastri for the University of Toronto Alumni award 2023 for Outstanding Contribution to Radiation Medicine and the UTDRO community 🎉🎊🎉 Here's Dr Jayant Sastri, @ReenaEngineer & @RajivSarin5 proudly collecting the award on your behalf! @RadMedPM @marykge

1/ #ASTRO23 HA-PCI for SCLC presented by Dr Gondi NRG CC003 @lisakachnic1 @BenLok

Twice daily radiotherapy to 54Gy BID ⬆️⬆️ OS and PFS in small cell #lungcancer as compared to 45Gy BID. compared to CONVERT and RTOG, higher once daily RT did not ⬆️ OS. #lcsm - abstract ➡️ shorturl.at/huDJ2 - time to change?

PACE-B 5-years results presented at #ASTRO23 by @nickva1 👉 excellent outcome of >95% biochemical control in SBRT 👉 no difference in long-term toxicity STANDARD OF CARE for favourable intermediate risk prostate cancer